The efficacy and safety of definitive concurrent chemoradiotherapy for non-operable esophageal cancer.

ABSTRACT:

Objective

To report outcomes and toxicity in patients who received definitive concurrent chemoradiation (DCCRT) for non-operable esophageal cancer (EC) in the modern era, and to identify markers of overall and disease-free survival (OS/DFS).

Methods

We conducted a retrospective cohort study of patients with unresectable EC who received DCCRT at our institution between 1/2008 and 1/2019. Descriptive statistics were used to report disease-control outcomes and CTCAE v4.0-5.0 toxicities. Univariable and multivariable Cox regression, and stepwise regression were used to identify associations with survival.

Results

At a median follow-up of 19.5 months, 130 patients with adenocarcinoma (AC) (62%) or squamous cell carcinoma (SCC) (38%) were evaluable (Stage II-III: 92%). Pati

SUBMITTER: Dreyfuss AD 

PROVIDER: S-EPMC7926027 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature